Cargando…
Clinical Trials of Stem Cell Treatment for Spinal Cord Injury
There are more than one million patients worldwide suffering paralysis caused by spinal cord injury (SCI). SCI causes severe socioeconomic problems not only to the patients and their caregivers but also to society; therefore, the development of innovative treatments is crucial. Many pharmacological...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7313002/ https://www.ncbi.nlm.nih.gov/pubmed/32498423 http://dx.doi.org/10.3390/ijms21113994 |
_version_ | 1783549857965801472 |
---|---|
author | Yamazaki, Kazuyoshi Kawabori, Masahito Seki, Toshitaka Houkin, Kiyohiro |
author_facet | Yamazaki, Kazuyoshi Kawabori, Masahito Seki, Toshitaka Houkin, Kiyohiro |
author_sort | Yamazaki, Kazuyoshi |
collection | PubMed |
description | There are more than one million patients worldwide suffering paralysis caused by spinal cord injury (SCI). SCI causes severe socioeconomic problems not only to the patients and their caregivers but also to society; therefore, the development of innovative treatments is crucial. Many pharmacological therapies have been attempted in an effort to reduce SCI-related damage; however, no single therapy that could dramatically improve the serious long-term sequelae of SCI has emerged. Stem cell transplantation therapy, which can ameliorate damage or regenerate neurological networks, has been proposed as a promising candidate for SCI treatment, and many basic and clinical experiments using stem cells for SCI treatment have been launched, with promising results. However, the cell transplantation methods, including cell type, dose, transplantation route, and transplantation timing, vary widely between trials, and there is no consensus regarding the most effective treatment strategy. This study reviews the current knowledge on this issue, with a special focus on the clinical trials that have used stem cells for treating SCI, and highlights the problems that remain to be solved before the widespread clinical use of stem cells can be adopted. |
format | Online Article Text |
id | pubmed-7313002 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-73130022020-06-29 Clinical Trials of Stem Cell Treatment for Spinal Cord Injury Yamazaki, Kazuyoshi Kawabori, Masahito Seki, Toshitaka Houkin, Kiyohiro Int J Mol Sci Review There are more than one million patients worldwide suffering paralysis caused by spinal cord injury (SCI). SCI causes severe socioeconomic problems not only to the patients and their caregivers but also to society; therefore, the development of innovative treatments is crucial. Many pharmacological therapies have been attempted in an effort to reduce SCI-related damage; however, no single therapy that could dramatically improve the serious long-term sequelae of SCI has emerged. Stem cell transplantation therapy, which can ameliorate damage or regenerate neurological networks, has been proposed as a promising candidate for SCI treatment, and many basic and clinical experiments using stem cells for SCI treatment have been launched, with promising results. However, the cell transplantation methods, including cell type, dose, transplantation route, and transplantation timing, vary widely between trials, and there is no consensus regarding the most effective treatment strategy. This study reviews the current knowledge on this issue, with a special focus on the clinical trials that have used stem cells for treating SCI, and highlights the problems that remain to be solved before the widespread clinical use of stem cells can be adopted. MDPI 2020-06-02 /pmc/articles/PMC7313002/ /pubmed/32498423 http://dx.doi.org/10.3390/ijms21113994 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Yamazaki, Kazuyoshi Kawabori, Masahito Seki, Toshitaka Houkin, Kiyohiro Clinical Trials of Stem Cell Treatment for Spinal Cord Injury |
title | Clinical Trials of Stem Cell Treatment for Spinal Cord Injury |
title_full | Clinical Trials of Stem Cell Treatment for Spinal Cord Injury |
title_fullStr | Clinical Trials of Stem Cell Treatment for Spinal Cord Injury |
title_full_unstemmed | Clinical Trials of Stem Cell Treatment for Spinal Cord Injury |
title_short | Clinical Trials of Stem Cell Treatment for Spinal Cord Injury |
title_sort | clinical trials of stem cell treatment for spinal cord injury |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7313002/ https://www.ncbi.nlm.nih.gov/pubmed/32498423 http://dx.doi.org/10.3390/ijms21113994 |
work_keys_str_mv | AT yamazakikazuyoshi clinicaltrialsofstemcelltreatmentforspinalcordinjury AT kawaborimasahito clinicaltrialsofstemcelltreatmentforspinalcordinjury AT sekitoshitaka clinicaltrialsofstemcelltreatmentforspinalcordinjury AT houkinkiyohiro clinicaltrialsofstemcelltreatmentforspinalcordinjury |